Central TNF inhibition results in attenuated neurohumoral excitation in heart failure: a role for superoxide and nitric oxide.
This study examined the effect of central tumor necrosis factor-alpha (TNF) blockade on the imbalance between nitric oxide and superoxide production in the paraventricular nucleus (PVN) and ventrolateral medulla (VLM), key autonomic regulators, and their contribution to enhanced sympathetic drive in mice with congestive heart failure (CHF). We also used a TNF gene knockout (KO) mouse model to study the involvement of TNF in body fluid homeostasis and sympathoexcitation in CHF. After implantation of intracerebroventricular (ICV) cannulae, myocardial infarction (MI) was induced in wild-type (WT) and KO mice by coronary artery ligation. Osmotic mini-pumps were implanted into one set of WT + MI/Sham mice for continuous ICV infusion of Etanercept (ETN), a TNF receptor fusion protein, or vehicle (VEH). Gene expressions of neuronal nitric oxide synthase (NOS) and angiotensin receptor-type 2 were reduced, while those of inducible NOS, Nox2 homologs, superoxide, peroxynitrite and angiotensin receptor-type 1 were elevated in the brainstem and hypothalamus of MI + VEH. Plasma norepinephrine levels and the number of Fos-positive neurons were also increased in the PVN and VLM in MI + VEH. MI + ETN and KO + MI mice exhibited reduced oxidative stress, reduced sympathoexcitation and an improved cardiac function. These changes in WT + MI were associated with increased sodium and fluid retention. These results indicate that elevated TNF in these autonomic regulatory regions of the brain alter the production of superoxide and nitric oxide, contributing to fluid imbalance and sympathoexcitation in CHF.
Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, 1909 Skip Bertman Drive, Baton Rouge, LA 70803, USA.
Anuradha
A
Guggilam
Jeffrey P
JP
Cardinale
Nithya
N
Mariappan
Srinivas
S
Sriramula
Masudul
M
Haque
Joseph
J
Francis
D000818:Animals; D001933:Brain Stem / Q000378:metabolism*; D016207:Cytokines / Q000378:metabolism; D018450:Disease Progression; D000068800:Etanercept; D006333:Heart Failure / Q000378:metabolism* / Q000503:physiopathology; D006706:Homeostasis; D007074:Immunoglobulin G / Q000378:metabolism; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D009203:Myocardial Infarction / Q000378:metabolism / Q000503:physiopathology; D009569:Nitric Oxide / Q000378:metabolism*; D010286:Paraventricular Hypothalamic Nucleus / Q000378:metabolism*; D044140:Receptor, Angiotensin, Type 1 / Q000378:metabolism; D018124:Receptors, Tumor Necrosis Factor / Q000378:metabolism; D012964:Sodium / Q000378:metabolism; D013481:Superoxides / Q000378:metabolism*; D013564:Sympathetic Nervous System / Q000503:physiopathology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000378:metabolism*
D016207:Cytokines; D007074:Immunoglobulin G; D044140:Receptor, Angiotensin, Type 1; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D013481:Superoxides; D009569:Nitric Oxide; D012964:Sodium; D000068800:Etanercept
Circ Res. 2002 Apr 19;90(7):807-13
11964374
Hypertension. 2004 Jul;44(1):101-6
15159379
Hypertension. 2005 Sep;46(3):533-9
16116043
Basic Res Cardiol. 2010 Jan;105(1):139-50
19823892
Am J Physiol Heart Circ Physiol. 2005 May;288(5):H2271-9
15637113
J Clin Invest. 1996 Dec 15;98(12):2854-65
8981934
Hypertension. 2010 Mar;55(3):652-9
20142564
Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H599-609
17416605
Prog Biophys Mol Biol. 2004 Feb-Apr;84(2-3):217-32
14769437
Heart Fail Monit. 2002;3(1):2-7
12634882
Hypertension. 2010 Aug;56(2):297-303
20547972
Am J Physiol. 1995 Apr;268(4 Pt 2):R958-62
7733407
Basic Res Cardiol. 2009 May;104(3):228-37
19159057
Hypertension. 2002 Feb;39(2 Pt 2):519-24
11882601
Hypertension. 2002 Sep;40(3):335-41
12215476
Eur Heart J. 2006 Apr;27(7):875-81
16434410
Ann N Y Acad Sci. 2000;917:4-18
11268367
Am J Physiol Regul Integr Comp Physiol. 2001 Nov;281(5):R1734-45
11641147
Curr Pharm Des. 2005;11(8):973-84
15777248
Arch Biochem Biophys. 2002 Jun 15;402(2):218-26
12051666
J Cereb Blood Flow Metab. 2009 Mar;29(3):640-7
19127280
Circ Res. 2004 Jul 23;95(2):210-6
15192025
Circulation. 1979 Sep;60(3):547-55
455617
Brain Res Brain Res Rev. 2001 Oct;36(2-3):258-64
11690623
Neuroscience. 2010 Dec 15;171(3):852-8
20870012
Basic Res Cardiol. 2010 Mar;105(2):301-13
19629561
Eur J Heart Fail. 2007 Oct;9(10):967-73
17719272
J Am Coll Cardiol. 1998 Feb;31(2):391-8
9462584
Circulation. 1988 Jun;77(6 Pt 2):I40-54
2836110
J Hypertens. 2009 Mar;27(3):543-50
19330914
Eur J Heart Fail. 2008 Jul;10(7):625-34
18550427
Acta Neuropathol. 1998 Mar;95(3):229-34
9542587
Basic Res Cardiol. 2010 Nov;105(6):751-62
20680307
Circulation. 2004 Apr 6;109(13):1594-602
15023878
J Am Coll Cardiol. 2009 Mar 24;53(12):1013-20
19298913
Circulation. 1998 Apr 14;97(14):1382-91
9577950
Am J Physiol. 1998 Dec;275(6):H2140-6
9843814
Basic Res Cardiol. 2009 Jan;104(1):78-89
18836678
Circ Res. 1992 Mar;70(3):607-11
1537096
Circ Res. 2004 Feb 20;94(3):402-9
14684626
J Am Coll Cardiol. 1996 Apr;27(5):1201-6
8609343
Hypertension. 1990 Mar;15(3):274-83
2303285
Eur J Neurosci. 2001 Jul;14(2):327-41
11553283
Pharmacol Ther. 2010 Sep;127(3):295-314
20621692
Neuropathol Appl Neurobiol. 1994 Apr;20(2):209-11
8072668
Circ Res. 1999 Mar 5;84(4):417-23
10066676
Brain Res. 1997 Feb 21;749(1):157-60
9070643
Basic Res Cardiol. 2001 May-Jun;96(3):258-66
11403419
Circ Res. 2002 Nov 29;91(11):1038-45
12456490
Front Neuroendocrinol. 1997 Jul;18(3):292-353
9237080
J Virol. 2007 Nov;81(22):12307-15
17855522
Auton Neurosci. 2002 Jun 28;98(1-2):24-7
12144034
Am J Physiol Regul Integr Comp Physiol. 2006 Apr;290(4):R1035-43
16322353
Circulation. 2000 Jun 20;101(24):2863-9
10859294
Basic Res Cardiol. 2010 Jul;105(4):453-64
20091314